SeekingAlpha · Oct 19, 2026
BridgeBio Oncology: The KRAS Opportunity Hidden In The Selloff
BridgeBio Oncology's total equity value of $226 million is lower than its liquid assets of $344.1 million as of June 30. See why I rate BBOT stock a Buy.
BB
NASDAQ · BBOT
BridgeBio Oncology Therapeutics Inc.
Healthcare · Biotechnology
$2.64
Down-$0.02 (-0.75%)
Updated Oct 27, 2026, 6:08 AM
SID Score
3.0/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 1.03B
- P/E ratio
- -2.62
- Dividend yield
- 0.00%
- 52-week range
- $2.60 – $14.87
- Volume
- 483.08K
- Avg. volume
- 237.22K
Price performance · BBOT
BBOT price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 26, 2026
BBOT closed at $2.64 after 21 trading sessions, down 30.71% for the selected period.
- Last close
- $2.64
- Period change
- -30.71%
- Period low
- $2.64
- Period high
- $4.10
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 26, 2026 | $2.66 | $2.68 | $2.61 | $2.64 | 483.08K |
| Oct 23, 2026 | $2.83 | $2.83 | $2.60 | $2.66 | 737.35K |
| Oct 22, 2026 | $2.66 | $2.85 | $2.66 | $2.85 | 661.9K |
| Oct 21, 2026 | $2.71 | $2.855 | $2.66 | $2.68 | 942.24K |
| Oct 20, 2026 | $2.85 | $2.98 | $2.70 | $2.72 | 660.93K |
| Oct 19, 2026 | $2.84 | $2.90 | $2.79 | $2.85 | 695.64K |
| Oct 16, 2026 | $2.95 | $2.95 | $2.81 | $2.82 | 480.77K |
| Oct 15, 2026 | $2.90 | $3.304 | $2.86 | $2.95 | 473.89K |
| Oct 14, 2026 | $2.94 | $3.07 | $2.88 | $2.905 | 440.62K |
| Oct 13, 2026 | $3.24 | $3.34 | $2.93 | $2.95 | 505.68K |
| Oct 12, 2026 | $3.31 | $3.37 | $3.23 | $3.26 | 233.97K |
| Oct 9, 2026 | $3.43 | $3.50 | $3.295 | $3.31 | 471.95K |
| Oct 8, 2026 | $3.43 | $3.43 | $3.27 | $3.42 | 566.22K |
| Oct 7, 2026 | $3.46 | $3.57 | $3.36 | $3.44 | 321.39K |
| Oct 6, 2026 | $3.60 | $3.72 | $3.48 | $3.50 | 660.11K |
| Oct 5, 2026 | $3.88 | $3.88 | $3.575 | $3.60 | 481.65K |
| Oct 2, 2026 | $3.97 | $4.045 | $3.88 | $3.89 | 486K |
| Oct 1, 2026 | $4.05 | $4.10 | $3.82 | $3.94 | 1.36M |
| Sep 30, 2026 | $3.94 | $4.15 | $3.875 | $4.10 | 736.32K |
| Sep 29, 2026 | $3.83 | $4.02 | $3.80 | $3.92 | 537.35K |
| Sep 28, 2026 | $3.91 | $3.925 | $3.79 | $3.81 | 476.63K |
Latest BBOT news
The latest Smart Investors Daily articles mentioning BBOT.
Stock researchCompany · Overview
Company
Market Activity
Research & News
BBOT research
Overview
Company profile and research snapshot.
Company profile
BridgeBio Oncology Therapeutics Inc, formerly BridgeBio Oncology Therapeutics is a clinical-stage biotechnology company that aims to transform the lives of patients with cancers driven by RAS and PI3Ka, the two frequently mutated oncogenes.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $23.20
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 21, 2026 | Morgan Stanley | Overweight | — |
| Oct 20, 2026 | Oppenheimer | Outperform | — |
| Sep 11, 2026 | JP Morgan | Overweight | — |
| Sep 10, 2026 | Leerink Partners | Outperform | — |
| Sep 9, 2026 | Wedbush | Outperform | — |
News briefing
No generated briefing is available yet.
Yahoo · Oct 12, 2026
BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., Oct. 12, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc., or BBOT (NASDAQ: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced it awarded an inducement grant on October 10, 2026, under BBOT’s 2025 Inducement Plan as a material inducement to the employment of one individual hired by BBOT in September 2026. The employee received non-qualified stock options to purchase an aggregate 90,000 shares of BBOT c
Yahoo · Sep 12, 2026
BridgeBio Oncology Therapeutics (BBOT) Bets Big On A Narrower KRAS Playbook
On September 8, BridgeBio Oncology Therapeutics (NASDAQ:BBOT) released new clinical data for its lead KRASG12C inhibitor, BBO-8520, and used the moment to narrow its focus: the company is now prioritizing BBO-8520 paired with a checkpoint inhibitor in previously treated lung cancer patients, alongside combination work for its two earlier-stage assets, BBO-11818 and BBO-10203, in other […]
Benzinga · Sep 10, 2026
Leerink Partners Maintains Outperform on BridgeBio Oncology, Lowers Price Target to $27
Leerink Partners analyst Andrew Berens maintains BridgeBio Oncology (NASDAQ:BBOT) with a Outperform and lowers the price target from $39 to $27.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
